pitavastatin has been researched along with Squamous-Cell-Carcinoma-of-Head-and-Neck* in 2 studies
2 other study(ies) available for pitavastatin and Squamous-Cell-Carcinoma-of-Head-and-Neck
| Article | Year |
|---|---|
Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth.
Despite increasing knowledge on oral and esophageal squamous cell carcinoma (OSCC and ESCC), specific medicines against both have not yet been developed. Here, we aimed to find novel anticancer drugs through functional cell-based screening of an FDA-approved drug library against OSCC and ESCC. Pitavastatin, an HMGCR inhibitor, emerged as an anticancer drug that inhibits tumor growth by downregulating AKT and ERK signals in OSCC and ESCC cells. One of the mechanisms by which pitavastatin inhibits cell growth might be the suppression of MET signaling through immature MET due to dysfunction of the Golgi apparatus. Moreover, the sensitivity of tumor growth to pitavastatin might be correlated with Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mice; Mouth Neoplasms; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Triazines; Xenograft Model Antitumor Assays | 2021 |
Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer.
Radioresistance is a major hurdle in the treatment of head and neck squamous cell carcinoma (HNSCC). Here, we report that concomitant treatment of HNSCCs with radiotherapy and mevalonate pathway inhibitors (statins) may overcome resistance. Proteomic profiling and comparison of radioresistant to radiosensitive HNSCCs revealed differential regulation of the mevalonate biosynthetic pathway. Consistent with this finding, inhibition of the mevalonate pathway by pitavastatin sensitized radioresistant SQ20B cells to ionizing radiation and reduced their clonogenic potential. Overall, this study reinforces the view that the mevalonate pathway is a promising therapeutic target in radioresistant HNSCCs. Topics: Cell Line, Tumor; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Mevalonic Acid; Neoplasm Proteins; Proteomics; Quinolines; Radiation Tolerance; Radiation, Ionizing; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2019 |